Welcome to our dedicated page for Opthea SEC filings (Ticker: OPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opthea Limited filings document foreign-private-issuer reporting for a clinical-stage biopharmaceutical company focused on retinal disease therapies. Form 6-K reports furnish quarterly reports and cashflow materials, preliminary final results, corporate updates, AGM voting results, company-secretary governance changes, and Appendix 2A capital-structure notices.
The filing record also includes incorporation-by-reference disclosures tied to a Form S-8 registration statement and a Form 25 notice for the voluntary withdrawal of American Depositary Shares, each representing eight ordinary shares, from Nasdaq listing and registration. These filings record governance, reporting status, securities registration, and ADS capital-structure matters.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
Opthea Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish a press release announcing the appointment of a new company secretary. The report lists this press release as Exhibit 99.1 and is signed on behalf of Opthea by Executive Officer Jeremy Levin.